Colchicine Use for Familial Mediterranean Fever—Observations Associated With Long-term Treatment

AUTOR(ES)

Peters, Robert S.

RESUMO

Of 85 patients with familial Mediterranean fever receiving continuous prophylactic colchicine therapy, 62 (73 percent) have had a significant reduction in the severity and frequency of their attacks. All 62 have been observed for three years or more, for a total of 4,680 patient-months and a mean duration of 75.5 months. Of the 85 patients, 23 (27 percent) did not complete three years of treatment for a variety of reasons. Diarrhea was the most common side effect, necessitating reduction of colchicine dosage in 12 patients, but discontinuation of treatment in only one. No other significant side effects were observed. Continuous, prophylactic colchicine therapy is effective in preventing the recurrent febrile paroxysms of familial Mediterranean fever and is indicated in those patients who are incapacitated by frequent attacks or who are at risk for amyloidosis developing.

Documentos Relacionados

• Effective treatment of a colchicine‐resistant familial Mediterranean fever patient with anakinra
• Assessment of long-term plasma exchange for familial hypercholesterolaemia.
• Anti-interleukin-1 treatment among patients with familial Mediterranean fever resistant to colchicine treatment. Retrospective analysis
• Long-term treatment of Parkinson's disease with bromocriptine.
• Long-term treatment of multiple sclerosis with azathioprine